PT  - JOURNAL ARTICLE
AU  - Hooli, Basavaraj V.
AU  - Parrado, Antonio R.
AU  - Mullin, Kristina
AU  - Yip, Wai-Ki
AU  - Liu, Tian
AU  - Roehr, Johannes T.
AU  - Qiao, Dandi
AU  - Jessen, Frank
AU  - Peters, Oliver
AU  - Becker, Tim
AU  - Ramirez, Alfredo
AU  - Lange, Christoph
AU  - Bertram, Lars
AU  - Tanzi, Rudolph E.
TI  - The rare <em>TREM2</em> R47H variant exerts only a modest effect on Alzheimer disease risk
AID  - 10.1212/WNL.0000000000000855
DP  - 2014 Oct 07
TA  - Neurology
PG  - 1353--1358
VI  - 83
IP  - 15
4099  - http://n.neurology.org/content/83/15/1353.short
4100  - http://n.neurology.org/content/83/15/1353.full
SO  - Neurology2014 Oct 07; 83
AB  - Objectives: Recently, 2 independent studies reported that a rare missense variant, rs75932628 (R47H), in exon 2 of the gene encoding the “triggering receptor expressed on myeloid cells 2” (TREM2) significantly increases the risk of Alzheimer disease (AD) with an effect size comparable to that of the APOE ε4 allele.Methods: In this study, we attempted to replicate the association between rs75932628 and AD risk by directly genotyping rs75932628 in 2 independent Caucasian family cohorts consisting of 927 families (with 1,777 affected and 1,235 unaffected) and in 2 Caucasian case-control cohorts composed of 1,314 cases and 1,609 controls. In addition, we imputed genotypes in 3 independent Caucasian case-control cohorts containing 1,906 cases and 1,503 controls.Results: Meta-analysis of the 2 family-based and the 5 case-control cohorts yielded a p value of 0.0029, while the overall summary estimate (using case-control data only) resulted in an odds ratio of 1.67 (95% confidence interval 0.95–2.92) for the association between the TREM2 R47H and increased AD risk.Conclusions: While our results serve to confirm the association between R47H and risk of AD, the observed effect on risk was substantially smaller than that previously reported.AD=Alzheimer disease; ADNI=Alzheimer's Disease Neuroimaging Initiative; AgeCoDe=German Study on Ageing, Cognition and Dementia in Primary Care Patients; CI=confidence interval; FBAT=family-based association test; GSK=GlaxoSmithKline; GWAS=genome-wide association study; LOAD=late-onset Alzheimer disease; MAF=minor allele frequency; NIA=National Institute on Aging; NIA-LOAD=National Institute on Aging Genetics Initiative for Late Onset Alzheimer's Disease; NIMH=National Institute of Mental Health; OR=odds ratio; SNP=single nucleotide polymorphism; TGEN2=Translational Genomics Research Institute series 2; TREM2=triggering receptor expressed on myeloid cells 2